Detail
LncRNA Name | SLC6A9-5:2 |
Synonyms | SLC6A9, GCENSG, GLYT1 |
Region | NA Sequence |
Ensembl | NA |
RefSeq | NA |
Circulating | ✘ |
Drug-resisitant | ✔ |
Prognostic | ✔ |
MiRNA | ✘ |
Variant | ✘ |
TF | ✘ |
Methylation | ✘ |
Cancer Name | papillary thyroid cancer |
ICD-0-3 | M8260/3 |
Methods | microarray, qPCR, RNAi, Western blot, Luciferase reporter assay, Cell proliferation assay etc. |
Sample | PTC tissues, cell lines (TPC-1 and BCPAP) |
Expression Pattern | down-regulated |
Function Description | We demonstrated that SLC6A9-5:2 was remarkably downregulated in 131I-resistant thyroid cancer cell lines and 131I-insensitive patients and was positively correlated with Poly (ADP-ribose) polymerase 1 (PARP-1) expression and its activation. After downregulating SLC6A9 or blocking PARP-1 artificially, the sensitive thyroid cancer cells mostly displayed a tolerant phenotype under 131I exposure. Furthermore, SLC6A9-5:2 overexpression was positively correlated with PARP-1 mRNA and protein levels, which restored the sensitivity of resistant thyroid cancer cells. |
Pubmed ID | 28086241 |
Year | 2017 |
Title | LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction. |
External Links |
Links for SLC6A9-5:2 | GenBank HGNC lncrnadb Noncode |
Links for papillary thyroid cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.